The global pharmaceutical sector is under increasing pressure as rising trade tensions drive countries to introduce new tariffs on drug exports. These policy shifts are straining international supply chains and pushing operating costs sharply higher.
At the center of this global shake-up stands Merck & Co. (MRK), a name synonymous with blue-chip dividends. With patent protection for Keytruda, which accounts for about 40% of Merck’s pharma sales, set to expire in 2028, the clock is ticking for the company to chart its next growth chapter.
